Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14125305 | 0.92 | KDM4E (0.48) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL19152744 | 0.92 | KDM4E (0.48) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL19131751 | 0.86 | ALDH1A1 (0.53) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL12909377 | 0.85 | KDM4E (0.54) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL18237034 | 0.83 | KDM4E (0.40) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL12094903 | 0.80 | KDM4E (0.34) | KDM4EMAPK1HIF1AALDH1A1 | |
| SCHEMBL13998226 | 0.80 | PAOX (0.38) | KDM4EMAPK1HIF1APAOX | |
| SCHEMBL12891506 | 0.79 | KDM4E (0.64) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL12451661 | 0.79 | KDM4E (0.52) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL275563 | 0.79 | ALDH1A1 (0.56) | KDM4EMAPK1HIF1ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-11497757-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220184104-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | BLINKBIO INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220184104-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | BLINKBIO INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-11291731-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20210161921-A1 | Silanol Based Therapeutic Payloads | BLINKBIO, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210161921-A1 | Silanol Based Therapeutic Payloads | BLINKBIO, INC. | 2021-06-03 | — | — | US | disclosed |
| US-10716801-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10716801-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| EP-3294810-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | Blinkbio Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2017214491-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | BLINKBIO, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214491-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | BLINKBIO, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | KDM4E 3060/4885MAPK1 4565/4885HIF1A 656/4885 |
| US-11497757-B2 | Silanol based therapeutic payloads | CD47, CD4, BST2 | KDM4E 3288/4885MAPK1 4667/4885HIF1A 323/4885 |
| US-11291731-B2 | Silicon based drug conjugates and methods of using same | CD44, MSN, AS3MT | KDM4E 3060/4885MAPK1 4565/4885HIF1A 656/4885 |
| US-20210161921-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | KDM4E 3288/4885MAPK1 4667/4885HIF1A 323/4885 |
| US-10716801-B2 | Silanol based therapeutic payloads | CD47, CD4, BST2 | KDM4E 3288/4885MAPK1 4667/4885HIF1A 323/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | KDM4E 3060/4885MAPK1 4565/4885HIF1A 656/4885 |
| US-20220184104-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | CD47, CD4, BST2 | KDM4E 3288/4885MAPK1 4667/4885HIF1A 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.